Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in Parkinsonian rats

Journal of Neuroscience

Volumn 23, Issue 23, 2003, Pages 8302-8309

  Breysse, Nathalie ^a   Amalric, Marianne ^a   Salin, Pascal ^a  

^a CNRS   (France)

Author keywords

Cytchrome oxydase; Glutamate decarboxylase; In situ hybridization; MPEP; Parkinson's disease; Reaction time task

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; GLUTAMATE DECARBOXYLASE; METABOTROPIC RECEPTOR ANTAGONIST;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENTOPEDUNCULAR NUCLEUS; HYPERACTIVITY; IN SITU HYBRIDIZATION; MALE; METABOLIC ACTIVATION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REACTION TIME; RECEPTOR BLOCKING; SECOND MESSENGER; TASK PERFORMANCE;

EID: 0141856474     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-23-08302.2003     Document Type: Article

References (43)

1. Amalric M,Berhow M, Polis I,Koob GF (1993) Selective effects of low-dose D2 dopamine receptor antagonism in a reaction-time task in rats. Neuropsychopharmacology 8:195-200.
2. Amalric M,Baunez C,Nieoullon A (1995a) Does the blockade of excitatory amino acid transmission in the basal ganglia simply reverse reaction time deficits induced by dopamine inactivation? Behav Pharmacol 6:508-519.
3. Amalric M,Moukhles H,Nieoullon A,Daszuta A (1995b) Complexdeficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat. Eur J Neurosci 7:972-980.
4. 3H] Methoxymethyl-3-[(2-methyl-l,3 1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J Pharmacol Exp Ther 303:1044-1051.
5. Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ (2000) Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20:7871-7879.
6. Baunez C, Nieoullon A, Amalric M (1994) N-methyl-D-aspartate receptor blockade impairs behavioral performance of rats in a reaction time task: new evidence for glutamatergic-dopaminergic interactions in the striatum. Neuroscience 61:521-531.
7. Benabid AL, Krack PP, Benazzouz A, Limousin P, Koudsie A, Pollak P (2000) Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: methodologic aspects and clinical criteria. Neurology 55: S40-S44.
8. Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M (2002) Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 22:5669-5678.
9. Chase TN, Oh JD (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 23:S86-S91.
10. DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281-285.
11. Evarts EV, Teravainen H, Calne DB (1981) Reaction time in Parkinson's disease. Brain 104:167-186.
12. Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, Varney MA, Johnson EC, Hess SD, Rao SP, Sacaan AI, Santori EM, Velicelebi G, Kuhn R (1999) 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38:1493-1503.
13. Greenamyre JT, O'Brien CF (1991) N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 48:977-981.
14. Guridi J, Herrero MT, Luquin MR, Guillen J, Ruberg M, Laguna J, Vila M, Javoy-Agid F, Agid Y, Hirsch E, Obeso JA (1996) Subthalamotomy in parkinsonian monkeys. Behavioral and biochemical analysis. Brain 119:1717-1727.
15. Guttman M, Burkholder J, Kish SJ, Hussey D, Wilson A, DaSilva J, Houle S (1997) [11C]RT1 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 48:1578-1583.
16. Herrero MT, Levy R, Ruberg M, Luquin MR, Villares J, Guillen J, Faucheux B, Javoy-Agid F, Guridi J, Agid Y, Obeso JA, Hirsch EC (1996) Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum. Neurology 47:219-224.
17. Javitch JA, Strittmatter SM, Snyder SH (1985) Differential visualization of dopamine and norepinephrine uptake sites in rat brain using. J Neurosci 5:1513-1521.
18. Kita H, Kitai ST (1987) Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J Comp Neurol 260:435-452.
19. Krack P, Pollak P, Limousin P, Hoffman D, Xie J, Benazzouz A, Benabid AL (1998) Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain 121:451-457.
20. Lievens JC, Dutertre M, Forni C, Salin P, Kerkerian-Le Goff L (1997) Continuous administration of the glutamate uptake inhibitor L-transpyrrolidine-2,4-dicarboxylate produces striatal lesion. Brain Res Mol Brain Res 50:181-189.
21. Lorenc-Koci E, Konieczny J, Wolfarth S (1998) Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats. Brain Res 793:315-320.
22. Ma Y, Dhawan V, Mentis M, Chaly T, Spetsieris PG, Eidelberg D (2002) Parametric mapping of. Synapse 45:125-133.
23. Marino MJ, Wittmann M, Bradley SR, Hubert GW, Smith Y, Conii PJ (2001) Activation of group I metabotropic glutamate receptors produces a direct excitation and disinhibition of GABAergic projection neurons in the substantia nigra pars reticulata. J Neurosci 21:7001-7012.
24. Marino MJ, Awad-Granko H, Ciombor KJ, Conn PJ (2002) Haloperidol induced alteration in the physiological actions of group I mGlus in the subthalamic nucleus and the substantia nigra pars reticulata. Neuropharmacology 43:147-159.
25. Mathiesen JM, Svendsen N, Bräuner H, Thomsen C, Ramirez MT (2003) Positive allosteric modulation of the human metabotropic receptor 4 (hmGluR4) bySIB- 1893 and MPEP. Br J Pharmacol 138:1026-1030.
26. Ossowska K, Lorenc-Koci E, Wolfarth S (1994) Antiparkinsonian action of MK-801 on the reserpine-induced rigidity: a mechanomyographic analysis. J Neural Transm Park Dis Dement Sect 7:143-152.
27. Ossowska K, Lorenc-Koci E, Schulze G,Wolfarth S (1996) The influence of dizocilpine (MK-801) on the reserpine-enhanced electromyographic stretch reflex in rats. Neurosci Lett 203:73-76.
28. Ossowska K, Konieczny J, Wolfarth S, Wieronska J, Pilc A (2001) Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 41:413-420.
29. Parent A, Hazrati LN (1995) Functional anatomy of the basal ganglia. II The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Rev 20:128-154.
30. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, Ed 2. Sydney: Academic.
31. Phillips JM, Maidment NT (2002) The subthalamic nucleus (STN) mediates the anti-Parkinsonian effect of MPEP in an animal model of Parkinson's disease. Paper presented at the 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL, November.
32. Pullman SL, Watts RL, Juncos JL, Chase TN, Sanes JN (1988) Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease. Neurology 38:249-254.
33. Rouse ST, Marino MJ, Bradley SR, Awad H, Wittmann M, Conn PJ (2000) Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol Ther 88:427-435.
34. Salin P, Hajji MD, Kerkerian-Le Goff L (1996) Bilateral 6-hydroxydopamine-induced lesion of the nigrostriatal dopamine pathway reproduces the effects of unilateral lesion on substance P but not on enkephalin expression in rat basal ganglia. Eur J Neurosci 8:1746-1757.
35. Salin P, Manrique C, Forni C, Kerkerian-Le Goff L (2002) High-frequency stimulation of the subthalamic nucleus selectively reverses dopamine denervation-induced cellular defects in the output structures of the basal ganglia in the rat. J Neurosci 22:5137-5148.
36. Schmidt WJ (1994) Behavioral effects of NMDA-receptor antagonists. J Neural Transm Suppl 43:63-69.
37. Shigemoto R, Mizuno N (2000) Metabotropic glutamate receptors-immunocytochemical and in situ hybridization analyses. In: Handbook of chemical neuroanatomy, Vol 18 (Ottersen OP, Storm-Mathisen J, eds), pp 63-98. New York: Elsevier Science.
38. Spooren WP, Gasparini F, Bergmann R, Kuhn R (2000) Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6- (phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. Eur J Pharmacol 406:403-410.
39. Starr MS (1995) Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 19:264-293.
40. Testa CM, Standaert DG, Young AB, Penney Jr JB (1994) Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J Neurosci 14:3005-3018.
41. Vila M, Herrero MT, Levy R, Faucheux B, Ruberg M, Guillen J, Luquin MR, Guridi J, Javoy-Agid F, Agid Y, Obeso JA, Hirsch EC (1996) Consequences of nigrostriatal denervation on the τ-aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes. Neurology 46:802-809.
42. Vila M, Levy R, Herrero MT, Ruberg M, Faucheux B, Obeso JA, Agid Y, Hirsch EC (1997) Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA. J Neurosci 17:765-773.
43. Vila M, Perier C, Feger J, Yelnik J, Faucheux B, Ruberg M, Raisman-Vozari R, Agid Y, Hirsch EC (2000) Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements. Eur J Neurosci 12:337-344.